MedTrace Logo

Prostate Cancer Detection Screening MRI Protocol

NCT04175730 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2022-06-09

Study results available
· View outcomes & findings →

Summary

Whether a quantitative detection specfic magnetic resonance imaging (MRI) protocol improves prostate cancer (PCa) detection in biopsy naïve men is not adequately studied.

Conditions

Interventions

DEVICE

Ultrasound and MRI

A single subsequent ultrasound guided prostate biopsy with MRI fusion

DEVICE

Ultrasound

A single subsequent ultrasound guided prostate biopsy

Sponsors & Collaborators

  • University of Illinois at Chicago

    lead OTHER

Principal Investigators

  • Michael R Abern, MD · University of Illinois at Chicago

Study Design

Allocation
NON_RANDOMIZED
Purpose
SCREENING
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-20
Primary Completion
2020-12-14
Completion
2020-12-14
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04175730 on ClinicalTrials.gov